Vendiol

Quick links to important sections

Vendiol

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vendiol

Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral Film-coated tablet
Pharmacological Class Hormonal Contraceptive
Common Use Birth Control / Prevention of pregnancy
Origin Synthetic

What is Vendiol?

Vendiol is a prescription-only medicinal product classified as a Combined Oral Contraceptive (COC), used primarily for the prevention of pregnancy. It operates by utilizing a fixed combination of two synthetic hormones: Ethinyl Estradiol and Gestodene. This dual-component drug is categorized under the ATC code G03AA10, falling within the pharmacological class of Sex hormones and modulators of the genital system.

What Type of Contraceptive Is Vendiol?

Vendiol is a dual-hormone medication containing the synthetic estrogen Ethinyl Estradiol and the synthetic progestogen Gestodene. This specific combination—a low dose of estrogen paired with the third-generation progestin Gestodene—is clinically recognized for its contraceptive efficacy when used correctly. This formulation is characterized as a combined oral contraceptive (COC), distinguished from progestogen-only pills because it contains both hormonal components, providing a multi-layered mechanism for fertility regulation. Combined oral contraceptives are an effective method of birth control, leveraging hormonal components to consistently prevent the release of an egg necessary for conception.

Vendiol’s Composition, Form, and General Purpose

Vendiol is supplied as an oral film-coated tablet, a form specifically designed for oral administration and systemic absorption. The medication is entirely synthetic in origin, composed of the estrogen derivative Ethinyl Estradiol and the specific progestogen Gestodene. The general purpose of this synthetic hormonal tablet is birth control, offering users a method for the prevention of pregnancy by consistently suppressing the hormonal signals responsible for the monthly release of an egg. This predictable hormonal maintenance supports the medicine's core function in family planning.

Regulatory References

  1. National Library of Medicine (NIH) on COCs

What side effects are possible with Vendiol?

Possible side effects and safety information

Official regulatory documents categorize the safety profile of Vendiol based on clinical trial data and post-market surveillance reports, grouping adverse reactions by the affected System Organ Class (SOC) and frequency of occurrence.

Commonly Reported Adverse Reactions

Adverse reactions classified as common or very common (occurring in at least 1 in 100 people) typically involve various systemic classes. For this class of medication, often reported reactions include headache, acne, metrorrhagia (abnormal bleeding), breast pain, nausea, and changes in body weight.

Serious and Clinically Significant Adverse Reactions

The most serious safety concerns are typically highlighted in regulatory warnings and may include an increased risk of thromboembolic disorders, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). Specific precautions for use are also required due to the potential for hyperkalemia (elevated serum potassium), especially in patients with pre-existing conditions like renal impairment or adrenal insufficiency.

Classification Examples of Reactions (General Class)
Very Common Headache, menstrual cycle irregularities
Common Nausea, breast discomfort, abdominal pain, acne
Uncommon Depression, dizziness, thromboembolic events

Population-Specific and Safety Restrictions

The medication is formally contraindicated in individuals with a history of or current renal impairment, adrenal insufficiency, undiagnosed abnormal uterine bleeding, or liver tumors/hepatic impairment. Due to the potential for thromboembolic risks, caution is necessary, and discontinuation is mandatory if a thrombotic event occurs. Safety documentation also addresses considerations for use alongside other medications, particularly enzyme inducers, which may affect its efficacy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents classify acute overdose of combined oral contraceptives (Vendiol, containing Ethinyl Estradiol and Gestodene) as generally not associated with serious adverse effects or life-threatening complications. Treatment for an overdose is strictly supportive, as no specific antidote is available.

Documented Overdose Manifestations

If an overdose is suspected, regulatory prescribing information states that the following signs and symptoms may be observed:

  • Nausea
  • Vomiting
  • Withdrawal Bleeding (Vaginal Bleeding): This is a common and officially documented manifestation, sometimes occurring days after the event.
  • Breast Tenderness

Withdrawal bleeding is specifically noted in regulatory documentation as a possible occurrence in young girls following an overdose due to the hormonal components.

Required Emergency Action

In the event of any suspected overdose, official guidance from regulatory authorities mandates a specific action:

Action Required When to Seek Help
Seek immediate medical attention For any suspected overdose, regardless of whether symptoms are present.
Contact Professional Services Call a Poison Control Center or healthcare provider immediately for professional guidance and assessment.

Treatment is directed toward the management of the patient's symptoms (symptomatic treatment).

Therapeutic Uses of Vendiol

What Vendiol Treats: Main Uses and Benefits

The combined pill, which contains ethinyl estradiol and gestodene, is commonly used for assistance with pregnancy prevention and for managing symptoms related to systemic imbalance and cyclical activity. The medication is utilized in clinical settings for these primary indications.

1. Management of Distressing Menstrual Symptoms

Vendiol supports the easing of symptoms for gynecological conditions marked by disruptive cycles, including intense menstrual pain and cramping (dysmenorrhea) and heavy menstrual bleeding (menorrhagia). It is relevant in conditions involving irregular or unpredictable cycles. The benefit provided supports general well-being during symptomatic phases and assists with maintaining functional stability. This medication is commonly used to help manage the burden of cyclical symptoms that interfere with daily activities.

2. Supportive Relief of Hormone-Driven Manifestations

The medication helps manage symptom clusters associated with hormonal acne and severe premenstrual symptoms, such as those seen in Premenstrual Dysphoric Disorder (PMDD). The therapeutic benefit provides support that helps ease the overall symptom burden throughout the monthly cycle, assisting with functional stability. Key therapeutic indications include assistance with pregnancy prevention, supportive management of dysmenorrhea, management of menorrhagia, and supportive therapy for hormonal acne.


Quick Fact: Symptom Support
Symptom Category Menstrual Cycle Distress and Hormonal Imbalance
Symptom Cluster Intense pain/cramping, heavy flow, cycle irregularity, and hormonal acne
Benefit Provides support that helps ease the overall symptom burden

Regulatory References

  1. NIH MedlinePlus overview on oral contraceptives

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Vendiol?

Vendiol, a combined oral contraceptive, is indicated for females of reproductive potential who have attained menarche and seek pregnancy prevention. Eligibility is defined by official contraindications and specific health restrictions found in regulatory labeling.

Populations for Whom Use is Contraindicated

The medicine must not be used by individuals with a current or history of thromboembolic diseases (e.g., DVT, PE, stroke, or MI) or known hereditary predisposition for blood clots. Use is also contraindicated with known or suspected breast cancer, certain other hormone-dependent tumors, or severe hepatic (liver) disease until function is normalized. The label prohibits use in smokers over 35 years of age and in women with migraine with aura or uncontrolled hypertension.

Restricted and Non-Applicable Use

Vendiol is contraindicated during pregnancy and not recommended for nursing mothers. Use must be stopped at least four weeks before, and through two weeks after, major surgery involving prolonged immobilization. The medicine is not indicated for use in females who have not reached menarche or for those who are post-menopausal.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Vendiol (Ethinyl Estradiol and Gestodene) is primarily defined by the way other substances affect the plasma concentrations of the hormonal components, often resulting in altered systemic exposure.


Documented Interaction Patterns

Category Substance Examples Official Regulatory Outcome
Formal Contraindication Hepatitis C Drug Combinations (Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir) Co-administration is formally prohibited due to the risk of significant liver enzyme (ALT) elevations.
Enzyme Inducers Rifampicin, Carbamazepine, Phenytoin, St. John's wort Documentation states these decrease plasma concentrations of the contraceptive hormones via CYP3A4 induction, which can diminish effectiveness.
Enzyme Inhibitors Itraconazole, Fluconazole, Ketoconazole These are documented to increase the systemic exposure of Ethinyl Estradiol through CYP3A4 inhibition.
Timing Requirement Colesevelam Administration requires a mandatory separation of at least 4 hours between products to mitigate reduced hormone exposure.

Other substances are also documented to modify exposure. These include Atorvastatin and Rosuvastatin, which increase the AUC (total exposure) of Ethinyl Estradiol. Additionally, Ascorbic Acid (Vitamin C), Acetaminophen, and Grapefruit Juice are noted in regulatory documents for their potential to increase the plasma concentrations of the hormonal components. This interaction profile highlights specific restrictions and timing rules based on official metabolic and systemic regulatory findings.

Mechanism of Action

Vendiol, chemically a semi-synthetic vinca-alkaloid, functions as a spindle poison by targeting the cellular microtubule system. Its primary molecular interaction is the inhibition of tubulin polymerization, a process essential for the assembly of microtubules. This interference prevents the correct formation of the mitotic spindle apparatus, resulting in the interruption of chromosomal segregation. Intracellularly, this mechanism arrests the cell cycle predominantly at the G2/M phase checkpoint. The subsequent cellular stress and microtubule disarray activate downstream signaling cascades, including the induction of the p53 tumor suppressor gene and modulation of protein kinases like p21 WAF1/CIP1 and the Ras/Raf pathway. This sequence of events ultimately leads to the phosphorylation and inactivation of the anti-apoptotic protein Bcl-2. The reduced formation of the Bcl-2/BAX heterodimer stimulates the intrinsic pathway, culminating in the programmed cell death (apoptosis) of proliferating cells at the system level. Vendiol exhibits a demonstrated preferential binding to mitotic microtubules over axonal microtubules.

Dosage and Administration Information

How Vendiol is Used in Clinical Practice

Administration Route and Dosing Schedule

Vendiol, a combined oral contraceptive, is administered solely via the oral route. The standard dosage schedule involves taking one active tablet daily as part of a 28-day cycle. This fixed pattern typically consists of either 21 consecutive days of hormone-containing tablets followed by 7 hormone-free or inactive tablets, or 24 active tablets followed by 4 inactive tablets. This cyclic frequency pattern forms the structural basis of the drug's use.


Timing, Sequence, and Adherence

Tablets must be taken at approximately the same time every day to maintain consistent hormonal levels, and adherence to the sequence indicated on the blister packaging is a mandatory condition. Ingestion may occur with or without food and is often scheduled later in the day to support user adherence.


Procedural Constraints and Adjustments

Established clinical practice involves a fixed daily and cyclic frequency pattern. For specific populations, such as those postpartum or post-second-trimester abortion, standardized instructions guide that initiation should commence no sooner than day 21 to day 28. A critical constraint involves the procedure for managing missed doses: if an active tablet is missed by more than 12 hours, established procedures are applied. These procedures involve the temporary use of a non-hormonal back-up method for seven days to restore the necessary dosing pattern.

Recent Clinical Evidence

Research evidence / Overview of studies for Vendiol

Evidence for Preventing Pregnancy (Contraceptive Efficacy)

The primary use of Vendiol was studied for its ability to prevent pregnancy. This research relies on Randomized Controlled Trials (RCTs) and large observational studies where researchers monitored the rate of pregnancy incidence, often quantified using the Pearl Index. Findings described measurements of low pregnancy incidence when the medication was used consistently as directed. However, research highlights that results are influenced by patient adherence. Comparative evidence is lacking to directly compare the measured rate of this specific Ethinyl Estradiol/Gestodene combination against all other low-dose combined pills.

Evidence for Supportive Management of Menstrual Cycle Symptoms

Research was studied for its use in conditions characterized by functional limitations and periods of heightened symptoms. The evidence is derived from settings with varying symptom burdens, including RCTs and systematic reviews.

Research on Menstrual Pain and Cramping (Dysmenorrhea)

Studies monitored patient-reported outcomes describing perceived discomfort. Trials documented measured changes in pain scores. Studies report how symptoms evolved in the observed populations, describing patterns of change in pain intensity and monitoring the use of supplemental pain medications.

Research on Heavy Menstrual Bleeding (Menorrhagia)

For heavy menstrual bleeding, research examined outcomes related to physiological strain, such as the quantifiable reduction in menstrual blood volume. Studies monitored for changes in hematological parameters like iron levels. Findings described measurements of change in menstrual blood loss volume over defined time intervals.

Evidence for Supportive Management of Hormonal Acne

The medication was evaluated in trials for its use in women with hormonal acne. Researchers conducted RCTs and open-label studies, with key outcomes being the changes in acne lesion counts and the overall change in acne severity scores. Research describes patterns observed in the studies showing measurements of change in acne severity over several months. Comparative evidence is lacking between this formulation and all other progestogen-containing pills approved for acne.

Key Evidence Gaps and Areas of Research Uncertainty

Follow-up durations were limited in many supportive trials, providing limited information for long-term outcomes. Furthermore, long-term effects are not fully established regarding sustained remission of symptoms after the first year of use. The results apply only to the populations studied in the major trials, and research provides context but not individual predictions.

Key Studies & References

  1. ATC code G03AA10: European Medicines Agency (EMA) classification
  2. Oral Contraceptives: National Library of Medicine (NIH) MedlinePlus Overview on COCs
  3. Ethinyl Estradiol and Gestodene: NIH MedlinePlus Drug Information (for main uses and symptom support)

Frequently Asked Questions (FAQ)

Common questions about Vendiol (FAQ)


Q: How long does it typically take for Vendiol to start showing an effect?

Regulatory documents state that combined oral contraceptives are designed to prevent pregnancy by suppressing ovulation. Contraceptive effect is generally achieved after seven consecutive days of active tablets have been taken. To ensure reliability, official instructions specify that a non-hormonal back-up method is necessary for the initial week of the first cycle.


Q: What happens if I stop taking Vendiol suddenly?

Official information indicates that stopping the medication typically results in the return of fertility, which means pregnancy becomes possible. Regulatory information notes that withdrawal bleeding often occurs within a few days after discontinuing the active tablets.


Q: Are there any long-term health risks associated with using Vendiol?

Official documentation describes a potential increased risk of thromboembolic events, such as blood clots (DVT, PE, stroke), as a serious safety consideration associated with combined oral contraceptives. Warnings also address potential risks related to certain cancers or liver tumors that are quantified in regulatory warnings.


Q: Does Vendiol cause weight gain or weight loss?

Official information recognizes 'changes in body weight' as a commonly reported adverse reaction. Regulatory records classify both weight gain and weight loss as possible effects observed in individuals using the medication.


Q: How long do the side effects of Vendiol usually last?

Official information suggests that many common side effects, such as nausea or unexpected spotting, often occur primarily during the first few months of use. These effects may diminish over subsequent cycles as the individual adjusts to the hormonal components.


Q: What should I do if I miss a dose of Vendiol?

The official product information contains a detailed protocol for managing a missed dose. This protocol addresses the necessary actions based on factors like the length of time since the dose was due and the specific week of the pill cycle. Protocols typically involve consuming the last missed active pill as soon as it is remembered. For delays exceeding a defined limit, official instructions specify the necessity of using a back-up contraceptive method for seven consecutive days.


Q: Is Vendiol safe to take during pregnancy?

Regulatory documents formally classify Vendiol as contraindicated during pregnancy. The medication is not intended for use once pregnancy has occurred, and regulatory documents include the standard caution that hormonal components could potentially affect the developing fetus.


Q: Can a person take Vendiol while breastfeeding?

Official prescribing information states that Vendiol is generally not recommended for nursing mothers. Official information notes that the hormones may pass into breast milk, and caution is advised regarding potential effects on the quality or quantity of the milk supply.


Q: Why do some people experience stomach upset with Vendiol?

Stomach upset, including nausea and abdominal pain, is listed as a common adverse reaction in official documents. This is generally thought to be related to the body adjusting to the hormonal components. Regulatory warnings also note that severe vomiting or diarrhea can reduce the hormone absorption, which may compromise effectiveness.


Q: Is there a generic version of Vendiol available?

Vendiol contains the active ingredients Ethinyl Estradiol and Gestodene. This specific combination is widely manufactured and marketed internationally, and generic versions containing the same components may be available, depending on local regulatory approvals and market status.


Q: Does Vendiol need to be taken at a specific time of day?

The official protocol requires the tablet to be taken at approximately the same time every day. This adherence to a consistent schedule is necessary to maintain stable blood levels of the active hormones, which supports maximizing contraceptive effectiveness.


Q: Is Vendiol affected by sunlight exposure?

Combined oral contraceptives are sometimes noted in regulatory safety information for potentially causing the skin to be more sensitive to the sun. Official documentation advises caution regarding prolonged sun exposure, as combined oral contraceptives may increase the risk of skin discoloration (chloasma).


Q: What were the main populations included in the studies for Vendiol?

Clinical trials for this combined pill formulation typically included women of reproductive age (e.g., 18–45 years old) who were seeking contraception or management of conditions like acne or dysmenorrhea. Studies focused on populations who met the standard medical criteria and had no contraindications to hormonal therapy.


Q: Does the effectiveness of Vendiol decrease over time?

Official data indicates that the contraceptive efficacy of Vendiol, when used perfectly, is not documented to decrease over time. However, overall effectiveness may be reduced if patient adherence declines or if the user begins taking other medications that interfere with the hormonal components.


Q: What is the mechanism by which Vendiol helps with symptoms?

For the non-contraceptive benefits, such as for acne or heavy menstrual bleeding, the combined hormones primarily work by regulating the menstrual cycle. This regulation suppresses the body's natural hormonal fluctuations, which is associated with symptom improvement over defined time intervals.


Q: Can Vendiol be taken with vitamins?

Official interaction profiles note that certain vitamins, such as Ascorbic Acid (Vitamin C), may increase the systemic exposure of the hormonal components in Vendiol. The interaction profile for other vitamins is not always fully defined in official documents, and professional guidance is typically required to assess potential effects.


Q: Are there any specific laboratory tests required before starting Vendiol?

Regulatory guidance often recommends specific laboratory tests before starting combined oral contraceptives, especially if there is a family history of blood clotting issues or pre-existing conditions. These may include initial checks on liver function and tests for hereditary clotting disorders.


Q: Are there any dietary changes recommended while on Vendiol?

General dietary changes are not typically mandated by regulatory documents. However, official interaction profiles specifically note that consumption of Grapefruit Juice may increase the plasma concentrations of the hormonal components in Vendiol.


Q: Why is it important to check interactions with Vendiol?

Checking interactions is critical because certain substances, such as those that increase liver enzyme activity, are documented to lower the hormone levels in the blood. This reduction in hormone concentration may compromise the contraceptive efficacy of Vendiol.


Q: Are the side effects of Vendiol different for men versus women?

This question is not applicable, as regulatory documents specify that the medication is only indicated for use by females of reproductive potential for the prevention of pregnancy. Therefore, its documented side effects are specific to this population.


Q: Is Vendiol known to cause any allergic reactions?

As with any medication, regulatory sources caution that allergic reactions, though rare, can occur with Vendiol. Official advice emphasizes that serious symptoms like hives, swelling of the face, or difficulty breathing are safety concerns that should be reported.


Q: Can Vendiol affect fertility in men or women?

Official data indicates that combined oral contraceptives do not cause long-term infertility. The return to normal fertility following discontinuation is typically rapid, with most women resuming ovulation within the first few months.

How should Vendiol be stored and disposed of?

How to Store and Dispose of Vendiol?

The storage and handling of Vendiol must strictly follow the conditions specified in the regulatory labeling to maintain product stability.

Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at a temperature not exceeding 25 C (77 F).
Protection Keep the tablets protected from light and moisture.
Packaging Must remain in the original blister pack and outer carton until the time of use.
Child Safety Store the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Vendiol must not be disposed of via wastewater or ordinary household trash. Official instructions require the product to be taken to a suitable community or municipal collection point for pharmaceutical waste, according to local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vendiol found in:

A-Z Index: